
Opinion|Videos|October 7, 2024
ECOSPOR Trials and Data with Fecal Microbiota Spores, Live-BRPK Oral Capsules (VAS) for C. difficile Infections
Paul Feuerstadt, MD, FACG, AGAF, discusses the key findings from the phase 3 ECOSPOR clinical trial for fecal microbiota spores, live-brpk oral capsules (VAS).
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Discussion of key findings from the phase 3 clinical trial for fecal microbiota spores, live-brpk oral capsules (VAS).
- Comparing the two clinical trials, what were some significant differences between them?
Newsletter
Stay ahead of emerging infectious disease threats with expert insights and breaking research. Subscribe now to get updates delivered straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Contagion Live
1
CDC's Latest Hepatitis B Vaccine Guidance Serves as Example for Future Federal Vaccine Policy
2
Growing International Evidence Suggests Emerging Metallo-β-Lactamase Therapy Could Benefit US Clinicians
3
Addressing the Three Pillars of PPE in Caring for Patients with High-Consequence Infectious Disease
4
Antibiotic De-Escalation Demonstrates Advantages for Community-Onset Sepsis
5
































































































































































































































































































































